Published in Vaccine Weekly, July 15th, 1996
Problems with first generation adenoviral vectors include their limited foreign DNA carrying capacity as well as problems associated with the host immune response which is triggered by the production of viral proteins. This host immune response is believed to be ultimately responsible for the limited expression of the therapeutic gene.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly